| 000 | 01093 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250517051109.0 | ||
| 264 | 0 | _c20151116 | |
| 008 | 201511s 0 0 eng d | ||
| 022 | _a1532-8708 | ||
| 024 | 7 |
_a10.1053/j.seminoncol.2015.05.008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCallahan, Margaret K | |
| 245 | 0 | 0 |
_aClinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. _h[electronic resource] |
| 260 |
_bSeminars in oncology _cAug 2015 |
||
| 300 |
_a573-86 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies _xpharmacology |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacology |
| 650 | 0 | 4 |
_aBiomarkers _xmetabolism |
| 650 | 0 | 4 |
_aCTLA-4 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIpilimumab |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 700 | 1 | _aWolchok, Jedd D | |
| 773 | 0 |
_tSeminars in oncology _gvol. 42 _gno. 4 _gp. 573-86 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1053/j.seminoncol.2015.05.008 _zAvailable from publisher's website |
| 999 |
_c25214255 _d25214255 |
||